热门资讯> 正文

Allogene Therapeutics任命Zachary Roberts为计划中的继任者

2026-05-29 05:29

Allogene疗法(ALLO) 0

Allogene Therapeutics (ALLO) said on Thursday that CEO David Chang will step down effective June 30 after eight years leading the company and will remain on its board of directors.
The company named Zachary Roberts, currently executive vice president of research and development and chief medical officer, as president and CEO, effective July 1.
Roberts will also join the board.

More on Allogene Therapeutics

Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript
Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M
Allogene Therapeutics GAAP EPS of -$0.18 beats by $0.01

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。